Finanzen von Fate Therapeutics Inc (FATE)FATEFate Therapeutics Inc

Evaluating the bottom line, Fate Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1495.39%, while the net margin is -1448.56%. These profitability ratios, combined with a Return on Equity (ROE) of -60.75%, provide a clear picture of how effectively FATE converts its operational activities into shareholder value.

In the context of the broader market, FATE competes directly with industry leaders such as OGCP and LCTX. With a market capitalization of $250.42M, it holds a significant position in the sector. When comparing efficiency, FATE's gross margin of 100.00% stands against OGCP's N/A and LCTX's 100.00%. Such benchmarking helps identify whether Fate Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Fate Therapeutics has a gross margin of 100%, indicating that it retains all revenue after direct costs, which is a strong positive. However, the company has been operating at a loss, with a net income of -31,590,000 USD in Q2 2026 and a negative EPS of -0.25.